NEW YORK (GenomeWeb News) – Horizon Discovery has licensed exclusive worldwide rights to a panel of human isogenic disease models developed by researchers from the University of Maryland, Baltimore, the firm said today.
The cell lines were developed using Horizon's Genesis platform. They will be added to the firm's X-Man cell models, which the Cambridge, UK-based firm said enables drug discovery researchers to "understand how cancer manifests itself in real patients and helps rationalize many aspects of drug development, and therefore the final cost of new personalized cancer therapies."
Horizon will pay the University of Maryland, Baltimore, up-front fees and royalties on product sales. The term of the license is seven years.